• NRW.BANK took an equity stake via its NRW.SeedCon program in Phagestack, a Pulheim-based biotech founded in 2023.
• Phagestack develops a data-driven platform that uses machine learning with in-house lab work to create targeted antimicrobial therapies.
• Funding supported the opening of a dedicated laboratory at BioCampus Cologne, expanding wet-lab validation alongside its digital discovery platform.
• The company targets antibiotic-resistant bacteria, with a focus on bacteriophages designed to act selectively against specific pathogens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRW Bank published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.